Industrial Technology Research Institute

Hsiang-Wen Tseng

Chih-Peng Liu

Ming-Cheng Wei

Ya-Chin Lo

Hsiang-Fa Liang

Jui-Hsiang Chen

I-Horng Pan

Yi-Cheng Cheng

Zong-Keng Kuo

Tien-Soung Tong

Hsin-Chieh Wu

Maggie J M Lu

Chia-Mu Tu

Maggie Lu

Min-Ying Lin

I-Huang Lu

Hsin-Jan Yao

Chun-Min Liu

Yi-Ting Hsieh

Mei-Wei Lin

Shuen-Hsiang Chou

Tse-Min Teng

Ching-Huai Ko

Shyh-Horng Lin

Shih-Ta Chen

Chun-Chung Wang

Yi-Man Chou

Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C-Calkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C-Calkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.

Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis

The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of an extract ofor an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of an extract ofor an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Pharmaceutical compositions and method for inhibiting angiogenesis

The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C-Calkane, wherein the modified histidine and the polymer or C-Calkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C-Calkane is about 0-40%.

Biomedical composition

Growing community of inventors

Taipei, Taiwan

Hsiang-Wen Tseng